Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: ALVESCO

« Back to Dashboard

Alvesco is a drug marketed by Takeda Gmbh and is included in one NDA. It is available from two suppliers. There are eight patents protecting this drug.

The generic ingredient in ALVESCO is ciclesonide. There are seven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ciclesonide profile page.

Summary for Tradename: ALVESCO

Patents:8
Applicants:1
NDAs:1
Suppliers: see list2

Clinical Trials for: ALVESCO

ATEM (Alvesco Non-interventional Study)
Status: Completed Condition: Asthma; Allergy

Omnaris Versus Levocetirizine Phase 4 Study
Status: Completed Condition: Allergic Rhinitis

Asthma Care With Alvesco® (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010/CA-102)
Status: Completed Condition: Asthma

Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis
Status: Completed Condition: Perennial Allergic Rhinitis

A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)
Status: Completed Condition: Perennial Allergic Rhinitis

Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis
Status: Recruiting Condition: Asthma; Allergic Rhinitis

Ciclesonide for the Treatment of Airway Hyperresponsiveness
Status: Completed Condition: Asthma

A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)
Status: Completed Condition: Seasonal Allergic Rhinitis

Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in Russia
Status: Recruiting Condition: Seasonal Allergic Rhinitis

To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405)
Status: Completed Condition: Rhinitis, Allergic, Perennial; Hay Fever

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Gmbh
ALVESCO
ciclesonide
AEROSOL, METERED;INHALATION021658Jan 10, 2008RXYes5,482,934<disabled>YY<disabled>
Takeda Gmbh
ALVESCO
ciclesonide
AEROSOL, METERED;INHALATION021658Jan 10, 2008RXYes5,605,674<disabled>Y<disabled>
Takeda Gmbh
ALVESCO
ciclesonide
AEROSOL, METERED;INHALATION021658Jan 10, 2008RXYes5,683,677<disabled>Y<disabled>
Takeda Gmbh
ALVESCO
ciclesonide
AEROSOL, METERED;INHALATION021658Jan 10, 2008RXNo5,775,321<disabled>Y<disabled>
Takeda Gmbh
ALVESCO
ciclesonide
AEROSOL, METERED;INHALATION021658Jan 10, 2008RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc